Last reviewed · How we verify
NCT06888193: BE CARING
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Phase 1 trial testing Bimekizumab in Moderate to Severe Plaque Psoriasis in 20 participants. Currently enrolling.
3 May 2027
Quick facts
| Lead sponsor | UCB Biopharma SRL |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 5 November 2025 |
| Primary completion | 3 May 2027 |
| Estimated completion | 3 May 2027 |
| Sites | 11 locations across Germany, Canada, Switzerland, United States, Spain |
Drugs / interventions tested
- Bimekizumab (BIMEKIZUMAB) — full drug profile →
Conditions studied
- Moderate to Severe Plaque Psoriasis — all drugs for Moderate to Severe Plaque Psoriasis →
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
- Axial Spondyloarthritis — all drugs for Axial Spondyloarthritis →
- Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →
Sponsor
UCB Biopharma SRL — full company profile →
Who can join
18 and older, female only, with Moderate to Severe Plaque Psoriasis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06888193
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bimekizumab
Trials testing the same drug.
- NCT07497620 — Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP · Phase 4 · not yet recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT07219420 — A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis · Phase 3 · recruiting
- NCT06742333 — Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? · Phase 2 · recruiting
- NCT06786936 — Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms · recruiting
Other recruiting trials for Moderate to Severe Plaque Psoriasis
Currently open trials in the same condition.
- NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
- NCT06506916 — A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Sever · Phase 3 · recruiting
- NCT06425549 — A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Ye · Phase 3 · recruiting
Other UCB Biopharma SRL trials
Trials by the same sponsor.
- NCT07465289 — A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gr · Phase 3 · not yet recruiting
- NCT07463521 — A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis · Phase 3 · not yet recruiting
- NCT07277660 — A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Stu · Phase 2 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT07286682 — A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06888193 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UCB Biopharma SRL
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06888193.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing